{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:42:45Z","timestamp":1740148965858,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12325-021-01704-y","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T07:04:53Z","timestamp":1617260693000},"page":"2709-2716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-0763","authenticated-orcid":false,"given":"Massimo","family":"Cugno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Gualtierotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Casazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Ghigliazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Torri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Montano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"1704_CR1","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763\u201370.","journal-title":"Lancet"},{"key":"1704_CR2","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","volume":"100","author":"RA Santos","year":"2003","unstructured":"Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1\u20137) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1704_CR3","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation"},{"key":"1704_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/S0140-6736(20)31131-4","volume":"395","author":"B Williams","year":"2020","unstructured":"Williams B, Zhang Y. Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19. Lancet. 2020;395:1671\u20133.","journal-title":"Lancet"},{"key":"1704_CR5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693\u20137.","journal-title":"Lancet"},{"key":"1704_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.18553\/jmcp.2010.16.9.671","volume":"1","author":"B Bian","year":"2010","unstructured":"Bian B, Kelton CM, Guo JJ, Wigle PR. ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm. 2010;1:671\u20139.","journal-title":"J Manag Care Pharm"},{"key":"1704_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s11096-015-0159-3","volume":"37","author":"SH Mahmoudpour","year":"2015","unstructured":"Mahmoudpour SH, Asselbergs FW, de Keyser CE, et al. Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. Int J Clin Pharm. 2015;37:1095\u2013103.","journal-title":"Int J Clin Pharm"},{"key":"1704_CR8","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431\u201340.","journal-title":"N Engl J Med"},{"key":"1704_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","volume":"395","author":"FJ de Abajo","year":"2020","unstructured":"de Abajo FJ, Rodr\u00edguez-Mart\u00edn S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705\u201314.","journal-title":"Lancet"},{"issue":"11","key":"1704_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11906-020-01101-w","volume":"22","author":"D Patoulias","year":"2020","unstructured":"Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou MS, Doumas M. Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities. Curr Hypertens Rep. 2020;22(11):90.","journal-title":"Curr Hypertens Rep"},{"key":"1704_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","volume":"146","author":"M Cugno","year":"2020","unstructured":"Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146:215\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1704_CR12","doi-asserted-by":"publisher","first-page":"102560","DOI":"10.1016\/j.jaut.2020.102560","volume":"116","author":"M Cugno","year":"2021","unstructured":"Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun. 2021;116:102560.","journal-title":"J Autoimmun"},{"key":"1704_CR13","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.","journal-title":"Lancet Respir Med"},{"key":"1704_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/FJC.0000000000000894","volume":"76","author":"AS Manolis","year":"2020","unstructured":"Manolis AS, Manolis TA, Manolis AA, Melita H. The controversy of renin-angiotensin-system blocker facilitation versus countering COVID-19 infection. J Cardiovasc Pharmacol. 2020;76:397\u2013406.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1704_CR15","unstructured":"European Society of Cardiology. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. 13 Mar 2020. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed Mar 2020."},{"key":"1704_CR16","unstructured":"American Heart Association, Heart Failure Society of America, American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 17 March 2020.\nhttps:\/\/newsroom.heart.org\/news\/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician?utm_campaign=sciencenews19-20&utm_source=science-news&utm_medium=phd-link&utm_content=phd03-17-20. Accessed Mar 2020."},{"key":"1704_CR17","doi-asserted-by":"publisher","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","volume":"296","author":"MJ Soler","year":"2009","unstructured":"Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296:F398-405.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1704_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","volume":"47","author":"RN Vuille-dit-Bille","year":"2015","unstructured":"Vuille-dit-Bille RN, Camargo SM, Emmenegger L, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015;47:693\u2013705.","journal-title":"Amino Acids"},{"key":"1704_CR19","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1038\/s41467-020-19145-6","volume":"11","author":"IT Lee","year":"2020","unstructured":"Lee IT, Nakayama T, Wu CT, et al. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat Commun. 2020;11:5453.","journal-title":"Nat Commun"},{"key":"1704_CR20","doi-asserted-by":"crossref","unstructured":"van de Veerdonk FL, Netea MG, van Deuren M, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife. 2020;9:e57555.","DOI":"10.7554\/eLife.57555"},{"key":"1704_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.V66.4.835.835","volume":"66","author":"D Smith","year":"1985","unstructured":"Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66:835\u20139.","journal-title":"Blood"},{"key":"1704_CR22","doi-asserted-by":"publisher","first-page":"105096","DOI":"10.1016\/j.phrs.2020.105096","volume":"160","author":"C Fang","year":"2020","unstructured":"Fang C, Schmaier AH. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein\/kinin and the renin-angiotensin systems. Pharmacol Res. 2020;160:105096.","journal-title":"Pharmacol Res"},{"key":"1704_CR23","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441\u20138.","journal-title":"N Engl J Med"},{"key":"1704_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosb\u00f8l","year":"2020","unstructured":"Fosb\u00f8l EL, Butt JH, \u00d8stergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324:168\u201377.","journal-title":"JAMA"},{"key":"1704_CR25","unstructured":"Di Castelnuovo A, Costanzo S, Antinori A, et al. RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascul Pharmacol. 2020:135:106805."},{"key":"1704_CR26","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/heartjnl-2020-317336","volume":"106","author":"ME Flacco","year":"2020","unstructured":"Flacco ME, Acuti Martellucci C, Bravi F, et al. Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis. Heart. 2020;106:1519\u201324.","journal-title":"Heart"},{"key":"1704_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30558-0","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021. https:\/\/doi.org\/10.1016\/S2213-2600(20)30558-0.","journal-title":"Lancet Respir Med"},{"key":"1704_CR28","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.dsx.2020.07.054","volume":"14","author":"TI Hariyanto","year":"2020","unstructured":"Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14:1463\u20135.","journal-title":"Diabetes Metab Syndr"},{"key":"1704_CR29","doi-asserted-by":"publisher","first-page":"100290","DOI":"10.1016\/j.obmed.2020.100290","volume":"19","author":"TI Hariyanto","year":"2020","unstructured":"Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020;19:100290.","journal-title":"Obes Med"},{"key":"1704_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nmeth.3587","volume":"12","author":"N Altman","year":"2015","unstructured":"Altman N, Krzywinski M. Association, correlation and causation. Nat Methods. 2015;12:899\u2013900.","journal-title":"Nat Methods"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01704-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T03:45:04Z","timestamp":1620618304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01704-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01704-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"23 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}